TCB is developing OmniCytex®, a proprietary universal stem cell treatment suitable for clinical applications. OmniCytex® is characterised by:

  • Minimal risk for development of GVHD
  • No limitation of source availability
  • Pluripotent characteristics but no tumorigenicity

Allogeneic stem cell transplantation (allo-SCT) has been suggested and trialled in relation to hematologic (blood) malignancies. However, a major disadvantage found in such therapies is the high incidence of graft failure and graft versus host disease (GVHD). GVHD is a complication that can occur when the newly transplanted donor cells attack indiscriminately the recipient’s body. HLA-matched donors have been utilised or depletion of the transplant’s T cells have been utilised, however the latter is considered to increase graft failure.

A number of potential stem cell sources have been found which include bone marrow-derived mesenchymal stem cells, tissue specific progenitor cell, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells that can be used to provide terminally differentiated cell types. Although the biological potentials of these stem cell types have been demonstrated, none of these respective cell types is widely accepted as a definitive cell source for clinical application.

Clinical Trials
In Market